30m
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results